[Therapy of cardiogenic shock in acute myocardial infarct]. 1994

G Görge, and M Haude, and D Baumgart, and S Sack, and J Ge, and R Leischik, and R Erbel
Abteilung für Kardiologie, Universität (Gesamthochschule) Essen.

Cardiogenic shock in acute myocardial infarction patients is the most common cause of in-hospital death. Various studies showed, that 60 to 100% of patients in cardiogenic shock will die, if no early reperfusion of their coronary artery could be established. The incidence of cardiogenic shock has decreased during the last years, most likely due to early thrombolytic therapy and administration of nitroglycerin. Reasons for cardiogenic shock are either necrosis of 40% or more of the left ventricular wall, right heart infarction, or complications which can be treated by the surgeon, like papillary muscle rupture, ventricular septal defect or rupture of the free ventricular wall. Diagnosis is based on clinical criteria, echocardiography, and on hemodynamic monitoring. The hemodynamic criteria for cardiogenic shock are a cardiac index of < 2.2/l, and an increased wedge pressure of > 18 mm Hg; additionally, diuresis is usually < 20 ml/h. Therapy can be divided into the following categories: a) pharmaceutical interventions to increase cardiac output like vasodilators or positive inotrope drugs; b) mechanical support systems; c) acute interventions with the aim of reperfusion; d) acute surgical interventions addressing complications like papillary muscle rupture, ventricular septal defect or rupture of the free ventricular wall. While steps a) and b) are able to stabilize the hemodynamical situation in patients with cardiogenic shock, they are rarely the definitive treatment. Point c), reperfusion of the coronary artery, can be divided in thrombolysis or acute PTCA. Thrombolysis failed to show a beneficial effect in most studies, either after intravenous or intracoronary application. On contrast, acute PTCA showed to be of great benefit in various studies with a technical success rate of 54 to 100% and a survival rate of patients from 58 to 100%. Thus, emergency PTCA is the treatment of choice in cardiogenic shock. Point d), surgical interventions can be divided in acute bypass grafting, which should be reserved for patients with severe multivessel disease, left main involvement, or failed PTCA. Furthermore, acute heart transplantation is effective, but will be possible in a minority of patients only. The last part of surgically manageable complications are surgery of papillary muscle rupture and ventricular septal defect. Results of early surgery in papillary muscle rupture or ventricular septal defects are much better than delayed interventions. Rupture of the free wall is usually a fatal event. In summary, the most successful therapy of cardiogenic shock is early emergency PTCA.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D002423 Cause of Death Factors which produce cessation of all vital bodily functions. They can be analyzed from an epidemiologic viewpoint. Causes of Death,Death Cause,Death Causes
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006342 Heart Rupture, Post-Infarction Laceration or tearing of cardiac tissues appearing after MYOCARDIAL INFARCTION. Post-Infarction Heart Rupture,Cardiac Rupture, Post-Infarction,Cardiac Rupture, Post Infarction,Cardiac Ruptures, Post-Infarction,Heart Rupture, Post Infarction,Heart Ruptures, Post-Infarction,Post Infarction Heart Rupture,Post-Infarction Cardiac Rupture,Post-Infarction Cardiac Ruptures,Post-Infarction Heart Ruptures,Rupture, Post-Infarction Cardiac,Rupture, Post-Infarction Heart,Ruptures, Post-Infarction Cardiac,Ruptures, Post-Infarction Heart
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012770 Shock, Cardiogenic Shock resulting from diminution of cardiac output in heart disease. Cardiogenic Shock
D015906 Angioplasty, Balloon, Coronary Dilation of an occluded coronary artery (or arteries) by means of a balloon catheter to restore myocardial blood supply. Angioplasty, Coronary Balloon,Angioplasty, Transluminal, Percutaneous Coronary,Coronary Angioplasty, Transluminal Balloon,Percutaneous Transluminal Coronary Angioplasty,Balloon Dilation, Coronary Artery,Transluminal Coronary Balloon Dilation,Angioplasties, Coronary Balloon,Balloon Angioplasties, Coronary,Balloon Angioplasty, Coronary,Coronary Balloon Angioplasties,Coronary Balloon Angioplasty
D015912 Thrombolytic Therapy Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts. Fibrinolytic Therapy,Thrombolysis, Therapeutic,Therapeutic Thrombolysis,Therapy, Fibrinolytic,Therapy, Thrombolytic,Fibrinolytic Therapies,Therapeutic Thrombolyses,Therapies, Fibrinolytic,Therapies, Thrombolytic,Thrombolyses, Therapeutic,Thrombolytic Therapies
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival

Related Publications

G Görge, and M Haude, and D Baumgart, and S Sack, and J Ge, and R Leischik, and R Erbel
May 1982, Deutsche medizinische Wochenschrift (1946),
G Görge, and M Haude, and D Baumgart, and S Sack, and J Ge, and R Leischik, and R Erbel
June 1997, Vnitrni lekarstvi,
G Görge, and M Haude, and D Baumgart, and S Sack, and J Ge, and R Leischik, and R Erbel
June 1995, Lijecnicki vjesnik,
G Görge, and M Haude, and D Baumgart, and S Sack, and J Ge, and R Leischik, and R Erbel
January 1984, Archivos del Instituto de Cardiologia de Mexico,
G Görge, and M Haude, and D Baumgart, and S Sack, and J Ge, and R Leischik, and R Erbel
September 1984, Kardiologiia,
G Görge, and M Haude, and D Baumgart, and S Sack, and J Ge, and R Leischik, and R Erbel
August 1970, Munca sanitara,
G Görge, and M Haude, and D Baumgart, and S Sack, and J Ge, and R Leischik, and R Erbel
January 1986, Vutreshni bolesti,
G Görge, and M Haude, and D Baumgart, and S Sack, and J Ge, and R Leischik, and R Erbel
August 1963, Cardiologia pratica,
G Görge, and M Haude, and D Baumgart, and S Sack, and J Ge, and R Leischik, and R Erbel
July 1991, Fel'dsher i akusherka,
G Görge, and M Haude, and D Baumgart, and S Sack, and J Ge, and R Leischik, and R Erbel
April 2022, Journal of clinical medicine,
Copied contents to your clipboard!